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Abstract: Using scatterplots of 2 or 3 parameters, diffuse optical tomog–
raphy and fluorescence imaging are combined to improve detectability of 
breast lesions. Small or low contrast phantom-lesions that were missed in 
the optical and  fluorescence  images  were detected in the scatterplots. In 
patient measurements, all tumors were visible and easily differentiated from 
artifacts and areolas in the scatterplots. The different rate of intake and wash 
out of the fluorescent contrast agent in the healthy versus malignant tissues 
was  also  observed  in  the  scatterplot:  this  information  can  be  used  to 
discriminate malignant lesion from normal structures. 
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1. Introduction 
Breast  cancer  detection  using  optical  imaging  methods  alone  is  hampered  by  a  lack  of 
specificity of the intrinsic optical properties and chromophore concentrations in breast tissue 
[1–3]. Indeed, the endogenous contrast from angiogenesis in tumors is nonspecific to cancer. 
Therefore, in case of small tumors or tumors in dense breast tissue this contrast is expected to 
be low. Furthermore, diffuse optical imaging has relatively low spatial resolution (on the order 
of  5-10  mm).  This  combination  of  low  contrast  and  low  spatial  resolution  of  the  diffuse 
optical  methods  results  in  limited  sensitivity  and  specificity  for  lesion  detection  and 
characterization, especially in case of small lesions and lesions located in dense breast tissue. 
The use of fluorescent contrast agents may increase the sensitivity and specificity of lesion 
detection and subsequently could provide a better and earlier diagnosis [4–8]. In the case of 
blood-pool contrast agent, the intravenously injected fluorescent molecules may preferentially 
accumulate in diseased tissue, because of firstly, an increased blood content due to tumor 
angiogenesis and secondly, leaky blood vessels in tumors due to damaged endothelial lining. 
In addition, the agent may have different decay properties in diseased tissue compared to 
normal tissue. This pharmacokinetic behavior could be used to localize tumors independently 
of the concentration of the fluorescent molecule [9]. 
In a clinical trial performed in 2007, a cyanine-based fluorescent dye (Omocianine) using 
the Philips Diffuse Optical Tomography (DOT) system dedicated for breast imaging has been 
evaluated [10]. The fluorescent contrast agent, Omocianine, circulates in the blood stream. 
Thus, the concentration of the contrast agent in normal tissue can be assumed proportional to 
the blood concentration. Further, the absorptions of the four wavelengths that were used by 
the DOT system (690 nm, 730 nm, 780 nm and 850 nm) are sensitive to blood content. Hence, 
the  more  blood  in  breast  tissue,  the  higher  the  absorption  and  the  more  fluorescence  is 
emitted.  Since  malignant  tumors  have  a  higher  permeability  of  their  blood  vessel  walls 
compared  to  healthy  tissue,  the  contrast  agent  tends  to  accumulate  at  the  tumor  location. 
Therefore, at equal amounts of blood, and hence equal absorption by blood, the fluorescence 
is higher in tumors than in healthy tissue. The study showed that DOT was feasible and safe 
for breast cancer visualization in patients, using low doses of Omocianine [10]. However, a 
serious limitation was the fact that the contrast agent Omocianine is a non-targeted fluorescent 
dye,  causing  fluorescent  enhancement  of  normal  tissues.  In  addition,  the  reconstruction 
algorithms produced artifacts in the fluorescence and absorption data, which might lead to 
clinical misinterpretation of the DOT images. 
In  this  study,  the  goal  is  to  increase  the  lesion  visibility  in  DOT  by  combining 
fluorescence and optical absorption data at the voxel level in one single graph, a scatterplot. 
This concept was introduced by Chance et al. in optical imaging of breast cancer [11]. They 
plotted the mean percentage of oxygen desaturation of blood versus the mean blood volume of 
their patients into a graph. Due to angiogenesis and high metabolism of cancers, data from 
breasts  with  cancer  were  found  at  high  blood  volume  and  high  percentage  of  oxygen 
desaturation of blood, corresponding to the upper right portion of the graph. Data from cancer 
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hypothesize  that  a  scatterplot  of  the  fluorescence  versus  the  absorption  will  improve  the 
separation  between  malignant  and  normal  tissue  within  one  breast.  In  this  scatterplot,  a 
parameter space is shown in which each dot corresponds to a single voxel in the breast. It 
should be emphasized that the parameter space does not show an image of the breast. Instead, 
the dimensions of the space correspond to physical parameters, fluorescence and absorption at 
a given wavelength. Then, the “grey level” of a voxel in the fluorescence image and the “grey 
level”  of  the  same  voxel  in  the  absorption  image  together  are  the  coordinates  of  the 
corresponding dot in the scatterplot. 
In addition, we aim to improve the specificity and sensitivity of the DOT procedure even 
further by adding a third dimension to the scatterplot, such as the absorption image of another 
specific  wavelength  or  total  hemoglobin  concentration.  The  fluorescence  and  absorption 
datasets are reconstructed with 2 different algorithms. Therefore, the reconstruction artifacts 
in the absorption and fluorescence images are unrelated. Thus, in the fluorescence-absorption 
scatterplot, we hypothesize that the signal from cancerous tissue will be enhanced, while the 
signals from artifacts will remain unchanged. 
The aim of this paper is to validate a method for breast cancer imaging using fluorescence 
and  optical  absorption  tomography  combined  in  a  scatterplot.  The  article  is  organized  as 
follows:  the  DOT  system,  the  phantom  experiments  and  clinical  measurements,  and  the 
scatterplot  are  described  first.  In  the  Results  section,  phantom  measurements  are  used  to 
validate the method under controlled circumstances. Phantom-lesions with a volume down to 
0.9 ml and a dye concentration ratio between lesion and background down to 2 are studied. 
Next, the increase of lesion visibility and the discrimination of structures from tumors in 5 
patients,  6  lesions,  are  investigated.  Due  to  the  physiology  of  breasts,  more  anatomical 
structures  are  visible  than  in  the  phantoms.  The  pharmacokinetics  of  the  cancerous  and 
healthy tissues are compared in scatterplots. Artifacts are discriminated from the lesions in the 
scatterplots. In conclusion, scatterplots provide a better  way to combine  fluorescence and 
absorption  data,  leading  to  improved  lesion  detection  and  better  discrimination  between 
malignant and other structures. 
2. Materials and methods 
2.1. Instrument 
The Philips DOT system used in this study combines a transmission mode and a fluorescence 
mode [10,12]. During a measurement, the patient, who received an intravenous injection of 
contrast agent, is lying in a prone position on the system bed with her breast suspended in a 
cup. A total of 507 optical fibers, 253 source and 254 detectors, were mounted alternatively 
on the surface of this measurement cup. The breast was illuminated sequentially from all sides 
with continuous wave light from solid-state lasers at four different near-infrared wavelengths 
(690, 730, 780, and 850 nm).The light emanating from the breast is detected simultaneously 
from all sides for each source position. To obtain optical coupling between fibers and breast 
and to prevent optical shortcuts around the breast, the cup is filled with a matching fluid, 
whose  optical  properties  (absorption  and  scattering)  are  similar  to  the  average  optical 
properties of breasts. 
In transmission mode, data are collected for the four wavelengths. In fluorescence mode, 
the fluorophore is excited at 730 nm and the fluorescent emission is collected by filtering out 
the excitation light in the detection path. The duration of the measurement is 9 minutes per 
breast; 4 minutes in total for the 4 transmission scans, and 5 minutes for the fluorescence scan. 
The detected signals are reconstructed into three-dimensional absorption images, one image 
per  wavelength,  and  into  a  three-dimensional  image  of  the  distribution  of  the  fluorescent 
contrast  agent.  Both  the  reconstructions  of  the  absorption  and  fluorescence  images  use 
algorithms based on first-order perturbation theory [13,14]. 
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Omocianine was injected intravenously. Immediately after injection, the agent circulates in 
the blood vessels and can then be found mainly in the blood. Over time, it is progressively 
washed out of the body by renal clearance. Since blood vessel walls in malignant tumors have 
a higher permeability compared to the blood vessels in healthy tissue, the contrast agent tends 
to permeate through the leaky  vessel  walls and to accumulate at  the  tumor location.  The 
results of the clinical study showed lesion-to-normal contrast ranging from 1.8 to 2.8 [10], 
with the contrast calculated by dividing the mean value in the lesion by the mean value of the 
background excluding the areola. 
The absorption and emission wavelength bands of Omocianine are presented in Fig. 1. The 
wavelength 730 nm is used as excitation wavelength for the Omocianine. 
 
Fig. 1. Normalized absorption, solid line, and emission, dotted line, spectra of Omocianine 
dissolved in human serum. The 730 nm wavelength used as excitation is indicated by the 
vertical line. 
2.3. Phantom 
We used 3 different double-cone shaped phantom-lesions, with a diameter of 20, 15 and 10 
mm and corresponding volumes of 2.1, 0.9 and 0.3 ml. According to the Susan G. Komen 
Foundation, the usual lesion-size detected with mammography ranges from 12 to 37.5 mm. 
Our phantom-lesions are in the lower range of the usual detection size of the mammogram. 
During a measurement, the phantom-lesion is suspended by a thin thread, invisible for DOT, 
at about half way down the cup and slightly decentered. To obtain contrast and thus mimic the 
specific extravasation of the dye in the tumor, higher concentration of contrast agent is used in 
the phantom-lesion than in the background. This set-up mimics a homogeneous breast held in 
the measurement cup with a single lesion in which the contrast agent has accumulated. 
The 3 phantom-lesion sizes can have different dye concentration and phantom-lesion-to-
background concentration ratios, presented in Table 1. The highest concentration ratio, 5, is 
used for validation purposes as this ratio will enable clear lesion visibility in the images. The 
other ratios, 2.5 and 2, are in the range of the typical lesion-to-normal contrasts of 1.8 to 2.8 
seen clinically with this scanner [10]. 
Table 1. Contrast agent concentrations (nM) in phantom-lesion and background for 
various lesion-to-background contrasts 
   Lesion-to-background concentration ratio 
   5  5  5  2.5  2 
In lesion  50  25  10  25  10 
In background  10  5  2  10  5 
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We  investigated  the  data  of  5  patients  previously  scanned  with  our  optical  fluorescence 
tomography system during a clinical trial. The study protocol was approved by the ethics 
committee, and written informed consent was obtained from all patients. A total of 6 lesions, 
1  invasive  lobular  carcinoma  and  5  invasive  ductal  carcinomas,  were  confirmed 
pathologically with core biopsy. Patient 4 had bilateral lesions. Patients’ information is shown 
in Table 2. Since the goals of the clinical study included the assessment of the diagnostic 
efficacy and target dose of the fluorescent contrast agent Omocianine, different doses of drug 
were administrated to different patient groups. 
In the 5 patients, baseline optical images were acquired for both breasts. Then Omocianine 
was injected intravenously in the patient. After injection, optical images were acquired up to 
24  hours,  with  8  and  5  imaging  time  points  for  the  ipsilateral  and  contralateral  breasts, 
respectively. The ipsilateral breast was scanned immediately, 30 minutes, 1 hour, 1.5 hours, 2 
hours, 4 hours, 8 hours, and 24 hours after the dye injection. The contralateral breast was 
scanned 1 hour, 2 hours, 4 hours, 8 hours and 24 hours after dye injection. 
Table 2. Patients’ information 
Patient  Age  Contrast agent dose (mg/kg)  Lesion type
a  Largest lesion size on MRI (mm) 
1  81  0.01  ILC  29 
2  59  0.01  IDC  18 
3  74  0.02  IDC  24 
4*  40  0.02  IDC and IDC  74 and 10 
5  55  0.02  IDC  34 
aIDC – Invasive Ductal Carcinoma; ILC – Invasive Lobular Carcinoma 
*Bilateral lesions 
2.5. Determination of total hemoglobin concentration 
For the spectral analysis, it was assumed that the total absorption of the probed sample is a 
linear combination of the different amount of absorption by the 4 main chromophores present 
in the breast: deoxy-hemoglobin (Hb), oxy-hemoglobin (HbO2), water and lipid. Their known 
absorption spectra allowed us to derive their concentrations from the 4 wavelengths. Then, the 
total hemoglobin concentration was determined by adding the calculated concentrations of 
oxy-hemoglobin and deoxy-hemoglobin. 
2.6. Scatterplots 
In scatterplots, a parameter space composed of 3-D images of the same object is plotted in a 
graph.  Each  dot  in  the  scatterplot  will  thus  correspond  to  one  voxel  in  the  image.  The 
dimensions of the parameter space are physical parameters; in this study, the fluorescence is 
first plotted as a function of the absorption at 690 nm. The accumulation of contrast agent at 
the tumor location likely increases the fluorescence signal in tumors, even in case of poor 
lesion-to-normal contrast in absorption due to angiogenesis. Hence, lesions are expected to 
correlate  with  high  fluorescence,  corresponding  to  the  upper  portion  of  the  scatterplot  of 
fluorescence  versus  absorption.  The  scatterplot  can  then  be  extended  with  additional 
information,  for  instance  in  the  form  of  a  color-scale.  For  this,  the  total  hemoglobin 
concentration  will  be  used  in  the  scatterplot  of  patient  measurements.  Indeed,  the  main 
absorber in tumors is hemoglobin. In case of phantom measurements, hemoglobin is absent, 
and the increase in absorption is due to the  higher concentration of contrast agent in  the 
phantom-lesion as compared to the background. Figure 1 shows that the absorption peak of 
the fluorescent contrast agent is located around 760 nm. Of our available laser wavelengths, 
780 nm is the wavelength that gives the highest absorption value of Omocianine. Hence, the 
reconstructed  absorption  at  780  nm  is  used  as  third  parameter  in  scatterplots  of  phantom 
measurements. Following this approach, the third dimension in the scatterplots is then related 
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For the use of 3 parameters, the scatterplot will be named 3-Parameter (3-P) scatterplot. 
The scatterplot is a technique to compare different parameters from multiple 3-D images 
of the same measurement. However, the information of the spatial location of the voxels is not 
preserved  in  the  scatterplot  itself.  Nevertheless,  any  areas  from  the  scatterplot  can  be 
correlated to voxels in the 3-D images, and vice-versa. 
3. Results 
3.1. Phantom measurements 
In Fig. 2 (a), an example of the typical morphology of the scatterplot of fluorescence versus 
absorption at 690 nm from a phantom measurement can be seen. The dots located in the upper 
right portion of the graph and in the form of a tail correspond to the phantom-lesion. As 
expected, they are located at high fluorescence and high absorption at 690 nm. Figures 2 (b) 
and (c) show the reconstructed fluorescence and absorption at 690 nm images, respectively, 
for the same phantom measurement. The arrow highlights that each dot in the scatterplot 
corresponds to one corresponding voxel in the 3-D images. 
 
Fig. 2. Measurement of the medium size phantom-lesion, with dye concentrations of 50 and 10 
nM for the lesion and background, respectively. (a) Scatterplot of the fluorescence versus the 
absorption at 690 nm. (b) Fluorescence image (arbitrary units). (c) Absorption image at 690 nm 
(mm
-1).  Every  dot  in  the  scatterplot,  (a),  corresponds  to  a  voxel  in  the  fluorescence  and 
absorption images in (b) and (c), respectively. 
Figure 3 presents the 3-P scatterplot of the same phantom measurements. As expected, the 
dots corresponding to the phantom-lesion voxels show high absorption at 780 nm. Similar 
results were observed for the large size phantom-lesions with any dye concentration and any 
concentration ratio between lesion and background.  
The scatterplots present the signal strength of one parameter per voxel as a function of the 
signal strength of another parameter measured for the same voxel. Hence, spatial information, 
and consequently information on lesion size is not present in the scatterplots. However, the 
location of the lesion in the breast can be determined from the scatterplots by correlating 
lesion dots in the scatterplot to the voxels in the image. 
In case of medium and small size phantom-lesions, similar results were observed except in 
four measurements. These 4 measurements correspond to 2 situations with both the medium 
and small phantom-lesions: first, with low lesion-to-background concentration ratio, i.e. 2, 
then with low dye concentration in lesion and background, i.e. 10 and 2 nM, respectively. In  
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Fig.  3.  3-P  scatterplot  of  the  fluorescence  versus  the  absorption  at  690  nm  and  with  the 
absorption at 780 nm in a form of a color-scale, of the measurement of the medium size 
phantom-lesion,  dye  concentrations  of  50  and  10  nM  for  the  lesion  and  background, 
respectively. The dots corresponding to the lesion-voxels show high absorption at 780 nm. 
 
Fig. 4. Measurement of the small phantom-lesion, with dye concentrations of 10 and 5 nM for 
the lesion and background, respectively. (a) Scatterplot of the fluorescence versus absorption at 
690 nm. (b) Absorption image at 690 nm (mm
-1). (c) Fluorescence image (arbitrary units). The 
green voxels in (c) correspond to the suspected area circled with the dashed line in (a). (d) 3-P 
scatterplot of the fluorescence versus the absorption at 690 nm and with the absorption at 780 
nm in a form of a color-scale. The area with voxels correlating to the phantom-lesion position 
is encircled. (e) Fluorescence image (arbitrary units). The voxels in red show the phantom-
lesion position and correspond to the dots circled in (d). 
these 4 measurements, the scatterplot did not show a tail shaped extension pointing at high 
fluorescence  and  high  absorption  values.  In  addition,  the  lesions  were  not  visible  in  the 
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in the fluorescence versus absorption at 690 nm scatterplot, (a), and in the absorption, (b), and 
fluorescence, (c), images. An area with high fluorescence signal in the scatterplot and circled 
with the dashed line in Fig. 4 (a) can be suspected to be the phantom-lesion. The voxels 
correlating with this area are shown in green in the fluorescence image in Fig. 4 (c): they do 
not correspond to the pre-defined phantom-lesion position which is half way down the cup 
and slightly decentered. However, in the 3-P scatterplot in Fig. 4 (d), an area is present with 
high  absorption  at  780  nm  in  the  portion  of  the  graph  with  relatively  high  fluorescence 
correlated. Indeed, the voxels correlated with this area in the 3-P scatterplot are located at the 
pre-defined position of the phantom-lesion in the cup in Fig. 4 (e). All the phantom-lesions 
were  detected  using  the  scatterplots;  Table  3  summarizes  the  scatterplot  in  which  the 
phantom-lesions were observed. 
Table 3. Summary of the lesion visibility in scatterplot of phantom measurements per 
lesion size
a 
   “Lesion-to-background” concentration ratio 
   5  5  5  2.5  22 
Concentrations of contrast agent (nM) 
Lesion  50  25  10  25  10 
Background  10  5  2  10  5 
Lesion visibility in scatterplot per lesion size 
Large  2-P  2-P  2-P  2-P  2-P 
Medium  2-P  2-P  3-P*  2-P  3-P* 
Small  2-P  2-P  3-P*  2-P  3-P* 
a2-P – lesion visible in the scatterplot of fluorescence and absorption at 690 nm; 3-P – lesion visible only in the 
scatterplot of fluorescence, absorption at 690 nm and absorption at 780 nm; * the phantom-lesion is not visible in the 
fluorescence and absorption images. 
In  Fig.  5  (a),  sparse  dots  around  the  main  shape  of  the  scatterplot  are  selected  and 
highlighted in red. The corresponding voxels in the fluorescence image are shown in red in 
Fig. 5 (b). These voxels are artifacts that were caused by the reconstruction algorithm and 
occurred at the fiber positions. It can be observed in the scatterplot in Fig. 5 (a) that the 
appearance  of  the  fiber  artifacts  is  very  distinct  from  the  appearance  of  the  rest  of  the 
scatterplot: the dots do not seem to accumulate together unlike the lesion dots. 
 
Fig. 5. Measurement of the medium size phantom-lesion, dye concentrations of 50 and 10 nM 
for  the  lesion  and  background,  respectively.  (a)  Scatterplot  of  the  fluorescence  versus  the 
absorption at 690 nm. (b) Fluorescence image. The red voxels in (b) correspond to the red dots 
selected in the scatterplot in (a). 
3.2. Patient measurements 
In Fig. 6, the scatterplots of the ipsilateral, (a), and contralateral, (b), breasts of patient 3 are 
presented. The corresponding fluorescence images of both breasts are shown in Figs. 6 (c) and 
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fluorescence  data  used  in  the  scatterplots  was  acquired  8  hours  after  the  injection  of  the 
contrast  agent.  The  lesion  is  observed  in  an  extension  of  the  scatterplot:  the  dots 
corresponding  to  the  lesion  voxels  are  highlighted  in  red.  Compared  to  phantom 
measurements a new feature, highlighted in green and located at high fluorescence and high 
absorption at 690 nm, appeared in the scatterplot: the areola. Without the extension due to the 
areola,  the  scatterplot  morphology  is  close  to  the  morphology  of  scatterplots  observed  in 
phantoms. In patient 4 with bilateral lesions, a scatterplot similar to the scatterplot of Fig. 6 (a) 
was observed for both breasts. 
 
Fig. 6. Patient 3. Scatterplots of the fluorescence at 8 hours after dye injection versus the 
absorption at 690 nm of (a) the ipsilateral breast and (b) the contralateral breast. The dots 
corresponding to the lesion and areola areas are highlighted in red and green, respectively. 
Fluorescence  image  at  8  hours  after  dye  injection  of  (c)  the  ipsilateral  breast  and  (d)  the 
contralateral breast. The red and green arrows point at the lesion and areola, respectively. 
Figure 7 presents the scatterplots of the ipsilateral and contralateral breasts of the same 
patient with fluorescence data acquired at different time points after the injection of contrast 
agent: 1 hour 30 minutes, 4 hours, 8 hours and 24 hours after injection. It can be observed that 
at 1 hour 30 minutes, in Fig. 7 (a), the dye has not yet accumulated in the tumor of the 
ipsilateral breast. Then, at 4 hours after dye injection, in Fig. 7 (c), the lesion was visible in 
the  scatterplot  of  the  ipsilateral  breast.  The  fluorescence  signal  from  the  areola  was  still 
increasing compared to the 1 hour and half measurement. At 8 hours after dye injection, in 
Fig. 7 (e), in the ipsilateral breast, the fluorescence signal from the lesion was similar to the 4 
hours post injection measurement, while the fluorescence signal from the areola was already 
decreased. In the contralateral breast, the fluorescence signal in the areola seems to increase 
until 8 hours after dye injection, in Figs. 7 (b), (d) and (f). Finally, 24 hours after injection, in 
Figs. 7 (g) and (h), the contrast agent was considerably washed out from both breasts. No 
structure similar to the lesion is observed in the scatterplots of the contralateral breast. From 
the scatterplots at the different time points, the specific pharmacokinetics of the lesion can 
clearly be observed. Note in Figs. 7 (c) and (e) that the tail shaped extension corresponding to 
the  lesion  points  at  lower  absorption  values  as  compared  to  normal  tissue.  Out  of  the  5  
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Fig. 7. Patient 1. Scatterplots at different time points for the ipsilateral, middle column, and 
contralateral, right column, breasts. The fluorescence data of these scatterplots were acquired at 
the time after injection of contrast agent indicated in the left column. The lesion dots are 
encircled with the solid line and the areola dots with the dashed line. 
patients,  this  patient  stands  alone  by  having  this  type  of  scatterplot  morphology  in  the 
ipsilateral breast. 
Figure 8 presents the 3-P scatterplots, including total hemoglobin concentration, of the 
ipsilateral breasts of patients 2 and 5. The fluorescence data used in these scatterplots were 
acquired 8 hours after the injection of the contrast agent. For these patients, 2 and 5, the signal 
from the areola was dominant over the signal from the lesion. However, the lesions were 
visualized in the 3-P scatterplot. 
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Fig. 8. 3-P scatterplots of the fluorescence at 8 hours after dye injection versus the absorption at 
690  nm  and  with  the  total  hemoglobin  concentration  (arbitrary  units)  as  colorscale.  (a) 
Ipsilateral breast of Patient 2. (b) Ipsilateral breast of Patient 5. The solid and dashed lines 
highlight the dots corresponding to the lesion and areola voxels, respectively. 
Figure  9  (a)  shows  an  example  of  false  positive  structures  in  the  fluorescence  image, 
highlighted with the red and green squares. These structures were not located in a suspicious 
area of the scatterplot, as can be seen in red and green in Fig. 9 (b); therefore, they can 
immediately be discriminated from the tumors in the scatterplot. 
 
Fig. 9. Patient 2. (a) Fluorescence image. Structures with high fluorescence are highlighted 
with the red and green squares. (b) Scatterplot of the fluorescence at 8 hours after dye injection 
versus the absorption at 690 nm. The dots corresponding to the voxels highlighted in a) are 
shown in red and green. 
4. Discussion 
Phantom measurements show that, first, 3-P scatterplots allow us to detect lesions that were 
not visible in the fluorescence and absorption images. Second, reconstruction artifacts are 
easily identifiable in the scatterplots. In patients, the lesions as well as artifacts and areola can 
be identified in specific areas of the scatterplots. The lesions could be discriminated from 
healthy tissue in scatterplots as a function of time. 
4.1. Phantom measurements 
In  the  15  phantom  measurements,  all  phantom-lesions  were  detected  in  the  2-P  or  3-P 
scatterplots, while only 11 lesions were detected in the fluorescence images, see Table 3. The 
4  phantom-lesions  visible  only  in  the  scatterplots  correspond  to  a  low  ratio  of  dye 
concentration  in  the  phantom-lesion  and  background,  small  phantom-lesion  or  low  dye 
concentration.  This  suggests  that  scatterplots  improve  lesion  detection  in  phantom 
measurements. 
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at the fiber positions- can limit the clinical interpretation of fluorescence images. However, 
these  artifacts  are  seen  as  sparse  dots  and  are  very  distinct  from  the  dense  area  of  dots 
corresponding to phantom-lesions in scatterplots. Therefore, they are easily identified in the 
scatterplots. 
4.2. Patient measurements 
The 6 investigated patient lesions were all identified in the 2-P or 3-P scatterplots, as shown in 
Table  3.  In  patients  1,  2,  3  and  5,  we  have  observed  in  the  scatterplot  that  the  area 
corresponding to the lesion of the ipsilateral breast does not exist in the scatterplot of the 
contralateral  breast.  This  confirms  the  absence  of  malignancy  in  the  contralateral  breast. 
Patient  4  has  bilateral  lesions  and  both  lesions  were  seen  in  the  scatterplots  of  the 
measurements of both breasts. 
In the scatterplots of all the 5 patients, the maximum absorption value at 690 nm was 
observed in the areola and the maximum fluorescence value in both the lesion and areola. 
Plotting the scatterplots for patient 1 over time, we have observed that the temporal variations 
of the dots corresponding to the lesion-voxels did not correlate with the temporal variations of 
the dots corresponding with healthy breast tissue, Fig. 7. The fluorescence contrast agent was 
retained in the tumor location and was thus eliminated from the tumor after the healthy tissue. 
Therefore, using the specific wash out rate of lesions in scatterplots can help discriminating 
cancer from healthy tissue. 
In the fluorescence images, many structures were visible, as seen for instance in Fig. 9. 
The  areola  is  sometimes  located  close  to  the  cup  wall  and  the  fiber  artifacts  can  be 
misinterpreted  as  the  areola  in  the  fluorescence  image.  However,  in  the  phantom 
measurements,  we  have  seen  that  the  fiber  artifacts  at  the  rim  of  the  cup  were  easily 
discriminated from the lesion in the scatterplot. In the absorption images, other types of tissue 
structures  can  be  expected  in  patient  measurements  due  to  the  assumption  in  the 
reconstruction algorithm that the scattering is constant over the breast volume. Indeed, the 
variations of scattering present in breasts are compensated in the reconstructed absorption 
images. The artifact structures in the fluorescence and absorption images perturb the lesion 
visualization and therefore the clinical interpretation of the images. Previous research showed 
that 5 of the 6 investigated lesions were visible in the fluorescence images [10]. However, 
without the information from the MRI and the pathologic examination, these lesions may have 
been  missed, because of the high number of non-malignant structures in the fluorescence 
images. Here, we showed that these non-malignant structures were clearly separated from the 
lesion area in the scatterplot. 
The contrast agent Omocianine used in this study does not specifically bind to a cancer-
associated target. Therefore, enhancement of other normal tissues is also possible, as we have 
seen  for  the  areola.  Glandular  tissue  is  vascularized  and  would  show  fluorescence 
enhancement that may mask signals from tumors. As we have seen in patient 1, whose breasts 
were mainly composed of fatty tissue, differences in pharmacokinetics are observed between 
tumors and normal tissue in the scatterplots plotted as a function of time, see Fig. 7. This 
method implied acquiring multiple images over several hours. This would become a burden 
for the patients when using Omocianine which has an uptake of several hours. For patient 
comfort, the method of detecting lesion in the scatterplot as a function of time should be used 
preferably  with  a  contrast  agent  with  shorter  pharmacokinetics.  Note  also  that  for  known 
uptake of a contrast agent, this method would in principle require measurements at only 2 
time-points;  one  measurement  after  the  dye  injection  and  the  other  measurement  at  the 
expected maximum contrast in lesion. 
Scatterplots as a function of time could in principle be also used to discriminate between 
cancerous tissue and glandular tissue. For instance, Fig. 10 presents the average fluorescence 
signal at 4 and 8 hours in the lesion, in red, and in suspected glandular tissue, in blue, in the 
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fluorescence signal in the lesion increases from 4 to 8 hours after dye injection, while the 
fluorescence  signal  in  the  suspected  glandular  tissue  decreases.  In  patient  5,  suspected 
glandular tissue was observed in the contralateral breast. However, we lacked data covering 
the washing out of the contrast agent, disabling the discrimination of the suspected glandular 
tissue  from  the  malignancy.  No  more  suspected  glandular  tissue  was  observed  in  the 
scatterplots of the other patients. In patients with dense breasts, tumors are frequently located 
in the glandular tissues. Moreover, it is known that mammography does not perform well with 
dense breasts. Here, our results suggest that we would be able to detect the presence of an 
abnormality  with  the  scatterplots  as  a  function  of  time.  Besides,  with  the  knowledge  of 
increased lesion visibility in case of low endogenous lesion contrast, as observed in phantom 
measurement,  one  can  expect  that  scatterplots  would  have  enhanced  sensitivity  for  lesion 
detection in dense breasts compared to the  separate absorption or fluorescence  images. It 
would be of great interest to perform a study with dense breasts to further investigate the 
discrimination between glandular tissue and malignancies. 
 
Fig. 10. Patient 2. Dye uptake at 4 and 8 hours after the injection of the fluorescent contrast 
agent in lesion, in red, and in suspected glandular tissue, in blue, of the contralateral breast. 
Generally,  the  lesions  in  the  scatterplot  were  located  at  relatively  high  absorption  as 
compared  to  the  background  tissue  excluded  the  areola.  In  addition,  they  were  pointing 
towards  high  fluorescence  values.  However,  in  patient  1,  the  lesion  was  located  at  high 
fluorescence but also at rather low absorption and it was pointing towards low absorption 
values,  Fig.  7.  One  may  think  that  this  effect  is  due  to  small  lesion  sizes  for  which 
angiogenesis is just starting or to low lesion-to-background absorption contrast. However, the 
lesion of patient 1 was not the smallest lesion of the study, see Table 2, and this effect was 
only observed in this patient. In addition, both lesions of patients 1 and 5 were missed in the 
absorption images, but the lesion of patient 5 was not located at low absorption values in the 
scatterplot, as shown in Fig. 8 (b). Interestingly, histopathology reported ILC in patient 1 and 
IDC for the rest of the patients. While IDC is structured as a lump, ILC is usually diffuse and 
infiltrates to the surrounding connective tissue [15]. The tumor blood vessels in ILC are thus 
likely  not  as  compacted  as  in  IDC.  While  the  fluorescent  dye  extravasates  at  the  tumor 
location independently of the vessels structures, the increase in absorption due to ILC may 
then not be locally as strong as in the IDC. This could explain why in the scatterplot, the 
structure of the ILC was seen at equally high fluorescence value as with IDC but at lower 
absorption values. This would suggest a potential in lesion characterization of the scatterplots. 
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Many research groups are now working on the development of targeted contrast agents. With 
this  new  type  of  contrast  agents,  only  cancerous  tissue  is  expected  to  show  fluorescence 
enhancement. The morphology of scatterplots of patients will then be certainly different: it 
might become similar to the morphology of the phantom scatterplots presented in this paper. 
Therefore, the issue of discrimination of healthy structures from malignancy can be overcome. 
However, problems with reconstruction artifacts and with small lesions or lesions deep inside 
the breast will remain. Therefore, the use of 3-P scatterplots has good potential for the next 
generation of contrast agents for breast cancer detection. 
4.4. Conclusion 
In conclusion, the combination of the scatterplots and the 3-D fluorescence, absorption and 
total hemoglobin concentration images improves the detection rate of lesions in DOT. 
Acknowledgments 
This work is supported by a European Commission Marie Curie contract MEST-CT-2004-
007832.The authors are grateful to Tim Nielsen for reconstructing the data. The authors also 
thank  Martin  van  Gemert  (Academic  Medical  Center,  Amsterdam,  the  Netherlands)  and 
Suzanne van den Berg-Dams (Philips Research, Eindhoven, the Netherlands) for correcting 
the manuscript. 
 
#143701 - $15.00 USD Received 4 Mar 2011; revised 24 Mar 2011; accepted 25 Mar 2011; published 30 Mar 2011
(C) 2011 OSA 1 April 2011 / Vol. 2,  No. 4 / BIOMEDICAL OPTICS EXPRESS  1020